On April 28, 2022, Dr. Yacov Geva signed an undertaking whereby Dr. Geva committed to finance the Company’s operations for a period of 12 months so long as he is the Company’s controlling shareholder, and/or the Company cannot be financed externally from any other sources, or until a sum of $10 million be received by the Company for its operations during 2022. In consideration therefor, the Company agreed to issued Dr. Geva 2,000,000 ordinary shares of the Company and an additional warrant to purchase 2,000,000 ordinary shares with an exercise price equal to the closing price of the Company’s ordinary shares on April 27, 2022.
page 85
GMV Price at posting:
3.9¢ Sentiment: None Disclosure: Held
